November 19, 2019 — Here is a list of the key late-breaking clinical study presentations and links to the results at the 2019 American Heart Association (AHA) annual meeting, Nov. 16-18, 2019, in Philadelphia. Find details on the AHA Scientific-Sessions.
AHA Late Breaking Science I – Outside the Box: New Approaches to CVD Risk Reduction
• DAPA-HF: The Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure Trial: Results in Nondiabetic Patients. Presented by John J. V. McMurray, BHF Cardiovascular Reseach Centre, Glasgow, United Kingdom.
• Safety and Efficacy of Inclisiran in Patients With ASCVD and Elevated LDL Cholesterol - Results From the Phase 3 ORION-10 Trial. Presented by R. Scott Wright, Mayo Clinic, Rochester, Minn.
• The COLchicine Cardiovascular Outcomes Trial (COLCOT). Presented by Jean-Claude Tardif | Montreal Heart Institute, Montreal, QC, Canada
• BETonMACE Looks at BET Protein Inhibition ACS and Diabetes. Presented by Kausik K. Ray, Imperial College of London, London, United Kingdom.
AHA Late Breaking Science II – Results for the Ischemia Trials: To Intervene or Not to Intervene
• ISCHEMIA - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes. Presented by Judith S. Hochman, NYU School of Medicine, New York, on behalf of the ISCHEMIA Research Group.
• International Study of Comparative Health Effectiveness With Medical and Invasive Approaches- Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes. Presented by Sripal Bangalore, New York University School of Medicine, New York, N.Y. on behalf of the ISCHEMIA-CKD Research Group
AHA Late Breaking Science III — Controversies in Contemporary Management of Aortic Stenosis (AS)
• Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Valve Replacement (TAVR) to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results. Presented by George Dangas, M.D., Mount Sinai Hospital, New York.
• Randomized Clinical Trial Comparing a Rivaroxaban-Based Strategy With an Antiplatelet-Based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves (GALILEO-4D). Presented by Ole De Backer, Rigshospitalet University Hospital, Copenhagen, Denmark.
• Balloon-Expandable versus Self-Expandable TAVR on Paravalvular Regurgitation and 2-Year Mortality: A Propensity-Matched Comparison From the FRANCE-TAVI Registry. Presented by Eric Van Belle, Institute Coeur Poumon - CHU Lille, Lille, France
• RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. Presented by Duk-Hyun Kang, Asan Medical Center, Seoul, Republic of Korea.
AHA Late Breaking Science IV – State of the Art Interventional Management for ACS Patients
• TWILIGHT-ACS: Ticagrelor with Aspirin or Alone in High-Risk Bleeding Patients after Coronary Intervention for Acute Coronary Syndrome. Presented by Usman Baber, Icahn School of Medicine at Mount Sinai, New York.
• Colchicine in Percutaneous Coronary Intervention. Presented by Binita Shah, VA New York Harbor Healthcare System, NYU School of Medicine.
• OCT COMPLETE: Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography (OCT). Presented by Natalia Pinilla Echeverri, McMaster University, Hamilton, Canada.
• COACT: One Year Outcomes of Coronary Angiography After Cardiac Arrest. Presented by Jorrit Lemkes, Amsterdam University Medical Center, Amsterdam, Netherlands.
• Mortality and Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Percutaneous Coronary Intervention With Impella vs Intra-Aortic Balloon Pump (IABP). Presented by Sanket Dhruva, M.D., UCSF School of Medicine, San Francisco.
• Comparative Effectiveness and Costs of Impella versus Intra-aortic Balloon Pump (IABP) in the United States. Presented by Amit P. Amin, M.D., Washington University School of Medicine, Saint Louis, Mo.
AHA Late Breaking Science V – Challenges in Heart Failure Management
• FUEL - Results From the Pediatric Heart Network’s Fontan Udenafil Exercise Longitudinal Trial. Presented by David J. Goldberg, Children's Hospital of Philadelphia, Philadelphia.
• Effect of Treatment According to Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF). Presented by Felipe Martinez, Insto Damic, Cordoba, Argentina.
• Effect of treatment measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure. Presented by John J. McMurray, BHF Cardiovascular Research Centre, Glasgow, United Kingdom.
• PARAGON-HF: LBCT: Effects of Sacubitril/Valsartan in Women Compared to Men With Heart Failure and Preserved Ejection Fraction. Presented by John J. McMurray, University of Glasgow, Glasgow, United Kingdom.
• PARAGON-HF Secondary Analysis: Effect of Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Presented by Scott D. Solomon, Brigham and Women's Hospital, Boston.
AHA Late Breaking Science VI – New Frontiers in Lipid Therapy
• EVAPORATE: Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides (200-499 mg/dl) on Statin Therapy. Presented by Matthew J. Budoff, M.D., Lundquist Institute and UCLA School of Medicine, Torrance, Calif.
• Safety and Efficacy of Inclisiran in Patients With Heterozygous Familial Hypercholesterolemia - Results From the Phase 3 ORION-9 Trial. Presented by Frederick J. Raal, Johannesburg Hospital, Johannesburg, South Africa.
• RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides. Presented by Christie M. Ballantyne, Baylor College of Medicine, Houston, Texas.
• RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects. Presented by Gerald F. Watts, University of Western Australia, Royal Perth Hospital, Perth, Australia.
• Benefit of a Target LDL Cholesterol Less Than 70 mg/dl After an Ischemic Stroke of Atherosclerotic Origin, the Treat Stroke to Target Trial Results. Presented by Pierre Amarenco, Paris University, Paris, France.
Other Key Studies Presented at AHA 2019:
Other Late-breaking Clinical Trials in 2019: